TGF-β1 is important for murine Th17 differentiation^[@R7],[@R8]^ and accordingly, transgenic expression of a mutant TGF-β subunit receptor II (CD4dnTGFβRII) in T cells interferes with the generation of Th17 cells in the setting of EAE^[@R11]^. We revisited this issue by assessing whether Th17 cells were present in the intestinal lamina propria of these mice. As expected, increased proportions and absolute numbers of IFN-γ-producing CD4^+^ T cells were present ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Of note, IL-17-producing CD4^+^ cells were also present; the proportions were reduced, but there were no differences in the absolute numbers between wild type and CD4dnTGFβRII mice ([Fig. 1a](#F1){ref-type="fig"}). We confirmed this finding using mice that lack TGF-β receptor subunit I in their T cells (*Tgfbr1*^f/f^CD4-Cre^+^ mice)^[@R12]^ ([Fig. 1b](#F1){ref-type="fig"}). Rorγt-expressing CD4^+^ lamina propria T cells were also present in *Tgfbr1*^f/f^CD4-Cre^+^ mice, whereas Foxp3^+^CD4^+^ T cells were dramatically reduced ([Fig. 1b](#F1){ref-type="fig"}). Collectively, these data argue that *in vivo* Th17 differentiation can occur in the absence of TGF-β signaling.

We next explored whether it was possible to differentiate naïve Th17 cells *in vitro* in the absence of TGF-β. Sorted naïve CD4^+^ T cells cultured in serum-free medium with no exogenous cytokines failed to produce *Il17a* mRNA ([Fig. 1c](#F1){ref-type="fig"}). The combination of IL-6, IL-1β and TGF-β1 efficiently induced *Il17a* mRNA, whereas IL-6 in the absence of TGF-β1 or IL-1β failed to do so. IL-23 alone failed to induce *Il17a* mRNA, but the combination of IL-6, IL-1β and IL-23 -- without TGF-β -- induced *Il17a* transcription ([Fig. 1c](#F1){ref-type="fig"}) and protein expression ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}).

To exclude the possibility that endogenously produced TGF-β might contribute to Th17 differentiation, we cultured cells in the presence of anti-TGF-β antibodies. These antibodies blocked Th17 differentiation induced by TGF-β1/IL-6/IL-1β and enhanced IL-2-production but had no significant effect on Th17 differentiation induced by IL-23/IL-6/IL-1β ([Fig. 1d, e](#F1){ref-type="fig"}). Similar results were also obtained in the absence of IL-1β and in medium supplemented with serum ([Supplementary Fig. 1c, d](#SD1){ref-type="supplementary-material"}). Anti-TGF-β antibodies blocked Foxp3-expression and Th17 differentiation over a wide concentration of exogenous TGF-β1, but had no effect on IL-23-dependent Th17 differentiation ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). TGF-β-independent Th17 differentiation by IL-23/IL-6/IL-1β was also confirmed using a TGF-β receptor serine kinase inhibitor (TGFβRi) ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}), and T cells from CD4dnTGFβRII and *Tgfbr1*^f/f^CD4-Cre^+^ mice ([Supplementary Fig. 2c, d](#SD1){ref-type="supplementary-material"}). IL-23/IL-6/IL-1β-induced expression of *Il21* and *Il22* were also unaffected by the TGFβRi ([Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}). In fact, Th17 cells generated with IL-23/IL-6/IL-1β showed enhanced IL-22 production compared to TGF-β/IL-6/IL-1β-induced Th17 cells ([Supplementary Fig. 2f](#SD1){ref-type="supplementary-material"}). IL-17F expression was similar under both conditions. Absence of TGFβR1 expression and disruption of TGF-β signaling in *Tgfbr1*^f/f^CD4-Cre^+^ T cells or in T cells treated with the TGFβRi were confirmed by the absence of SMAD2 phosphorylation and gene induction by TGF-β1 ([Supplementary Figs 2 g, h and 3 a, b](#SD1){ref-type="supplementary-material"}).

If our model is correct, an essential aspect of Th17 differentiation is the induction of IL-23R independently of TGF-β. We found that IL-6 and IL-1β induced *Il23r* mRNA expression in the absence of TGF-β. Addition of IL-23 significantly increased expression, whereas TGF-β1 inhibited expression ([Fig. 2a, b](#F2){ref-type="fig"}, [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Accordingly, the IL-23-mediated induction of the Th17 phenotype was altered by TGF-β1 ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). The inhibitory effect of TGF-β signaling on *Il23r* expression was also evident using the TGFβRi and in cells with impaired TGF-β signaling ([Supplementary Fig. 3e, f](#SD1){ref-type="supplementary-material"}). Since IL-23 and IL-6 exert their effects through STAT3, we also documented that STAT3 binds the *Il23r* locus using chromatin immunoprecipitation with massive parallel sequencing ([Fig. 2c](#F2){ref-type="fig"}).

We next determined if acquisition of permissive epigenetic modifications and extinction of repressive modifications of the *Il17a/f* and *Rorc* loci also occurred in the absence of TGF-β. In serum-free media, we found that in the presence of IL-6 and IL-1β, TGF-β and IL-23 were both effective in inducing histone 3 lysine 4 trimethylation (H3K4m3) of the *Il17a* and *Il17f* promoters ([Fig. 2d](#F2){ref-type="fig"}). Recruitment of the transcriptional co-activator, p300, also occurred in response to both factors, whereas stimulation with IL-6 and IL-1β alone resulted in loss of the repressive mark, histone 3 lysine 9 trimethylation (H3K9m3). While TGF-β1 appeared to be a more efficient inducer of *Rorc*, p300 was recruited to this locus in response to IL-23 and Rorγt protein induction was detected in the absence of TGF-β1 ([Fig. 2d](#F2){ref-type="fig"} and [Supplementary Fig. 3g](#SD1){ref-type="supplementary-material"}).

To compare IL-23/IL-6-induced Th17 \[Th17(23)\] cells with conventional Th17 cells \[Th17(β)\], we assessed global gene expression in both cells and found more than 2000 genes differentially expressed ([Supplementary Fig. 4a, b](#SD1){ref-type="supplementary-material"}). As shown in [Fig. 3a](#F3){ref-type="fig"}, conventional Th17(β) cells expressed higher levels of *Il9*, *Il10* and *Ccl20*, whereas Th17(23) cells expressed higher levels of *Il2*, *Il33* and *Il18r1*. These differences were confirmed by quantitative PCR and measurement of protein expression ([Fig. 3b](#F3){ref-type="fig"}, [Supplementary Fig. 4 c--e](#SD1){ref-type="supplementary-material"}). To assess whether IL-17-producing cells with a phenotype similar to those induced *in vitro* in the absence of TGF-β are generated *in vivo*, mice were immunized with ovalbumin and adjuvant. By day 7 the majority of IL-17-producing OT-II CD4^+^ T cells also expressed IL-18R1 and produced IL-2^[@R6]^ ([Supplementary Fig. 4f](#SD1){ref-type="supplementary-material"}). Collectively, these data support the *in vivo* relevance of TGF-β-independent generation of Th17 cells.

Conventional Th17(β) and IL-23-induced Th17(23) cells both expressed *Rorc*. As expected, Th17(β) cells expressed *Maf* and *Ahr* mRNA. In contrast, Th17(23) cells expressed *Tbx21* and *Hlx* mRNA ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 5a, b](#SD1){ref-type="supplementary-material"}) and T-bet protein ([Figures 3d, e](#F3){ref-type="fig"}). In the absence of T-bet, the proportion of IL-17-producing cells induced by IL-23/IL-6/IL-1β was increased ([Fig. 3f](#F3){ref-type="fig"}). Having demonstrated that Th17(23) cells retained T-bet expression, we wondered how this would influence cytokine production. As shown in [Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}, IL-23/IL-6/IL-1β induced slightly fewer IL-17-producing cells than the conventional pathway using TGF-β1. Expansion of cells in IL-2 and TGF-β1 resulted in reduction in IL-17 expression in both subsets. Th17 cells cultured in IL-12 acquired the ability to make IFN-γ^[@R13]^; however, this was significantly enhanced in Th17(23) cells. Previous studies have suggested that a major function of TGF-β is to downregulate T-bet and to prevent Th17 cells from acquiring the capacity to produce IFN-γ^[@R13],[@R14]^. We therefore performed transcriptional profiling on conventional Th17 cells cultured with TGF-β1 and IL-6 in the presence and absence of the TGFβRi. In addition to contributing to the changes observed in cytokines and chemokines ([Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}), we found that blocking TGF-β1 resulted in the upregulation of *Tbx21* and *Gata3* mRNA ([Supplementary Fig. 5a, d](#SD1){ref-type="supplementary-material"}).

It is well established that IL-23 is critical for the development of EAE, but T-bet is also critical, a finding that does not fit well with our current understanding of Th17 cell development^[@R15]^. The present findings suggest that Th17 cells, which arise in the absence TGF-β, would express RORγt and T-bet. To test if such cells are seen *in vivo*, we immunized *Rorc*(γt)-*Gfp*^TG^-reporter mice^[@R16]^ with myelin oligodendrocyte glycoprotein (MOG) 35--55 peptide. We found that approximately 25 to 60% of RORγt^+^ IL-17^+^ CD4^+^ cells in the CNS expressed T-bet ([Fig. 4a, b](#F4){ref-type="fig"}). Furthermore, a significantly higher proportion of the RORγt, T-bet double positive Th17 cell population is found within the CNS compared with RORγt single positive Th17 cells ([Fig. 4b](#F4){ref-type="fig"}).

To investigate the pathogenic potential of both subsets of Th17 cells, we isolated naïve T cells from TCR transgeneic (2D2) mice that recognize MOG35--55 peptide and differentiated them into Th17(23) cells in the presence of anti-TGF-β antibodies or alternatively into conventional Th17(β) cells resulting in higher percentage of IL-17-producing cells ([Fig. 4c](#F4){ref-type="fig"}). After adoptive transfer, Th17(23) cells provoked significantly more severe disease than that induced by Th17(β) cells ([Fig. 4d](#F4){ref-type="fig"}). This was associated with significantly greater total numbers of IL-17^+^ and IFN-γ T cells within the CNS ([Fig. 4e, f](#F4){ref-type="fig"}) and elevated numbers of double-producer T cells ([Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). In contrast, adoptive transfer of conventional Th17(β) cells were poorly pathogenic^[@R17]^ and preferentially trafficked to the spleen ([Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"}).

Though initial reports suggested that IL-23 was a driver of IL-17 production^[@R2],[@R18]--[@R20]^, the lack of IL-23R on naïve CD4^+^ T cells has been a factor in demoting this cytokine from an inducer of Th17 differentiation to a restricted role in Th17 expansion or preservation of pathogenicity^[@R6],[@R21]^. In its place, TGF-β1 has been proposed to be the primary inductive factor that specifies Th17 differentiation in conjunction with IL-6. The current data indicate that TGF-β is not always necessary. IL-6 acting via STAT3 induces *Il23r* transcription, and IL-23 further enhances its own receptor expression. These cytokines in conjunction with IL-1β are sufficient to induce transcription and epigenetic modification of the *Il17a/Il17f* and *Rorc* loci, independently of TGF-β1. These data thus shed light on previous contradictory data pertaining to mouse versus human Th17 differentiation and indicate that there may be no species-specific difference^[@R22]--[@R24]^.

The present data do not dispute that idea that TGF-β1 and IL-6 induce Th17 differentiation ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). TGF-β is ubiquitous and undoubtedly is present at sites of inflammation. However, it is clear that TGF-β1 inhibits T-bet expression^[@R13],[@R14]^. While this stabilizes the phenotype of selective IL-17 production, the Th17 cells generated in the presence of TGF-β1 and IL-6 are not pathogenic in the model tested and produce IL-9 and IL-10^[@R16],[@R17],[@R21],[@R25],[@R26]^. By contrast, Th17 cells derived in the presence of IL-23 appear to have greater pathogenic potential. They express T-bet and IL-18R1, which each are essential for the development of EAE^[@R15],[@R17],[@R27]^ and express CXCR3, which is important for trafficking of T cells to sites of inflammation^[@R28],[@R29]^. In addition, TGF-β1 suppresses IL-23R expression and IL-23-mediated IL-22 production. The diversity of IL-17-producing cells helps to resolve previously perplexing data in EAE, namely the limited pathogenicity of Th17 cells generated with TGF-β and the importance of STAT3, IL-23R^[@R5],[@R6],^, T-bet^[@R15],[@R17]^ and IL-18R1^[@R27]^. The expression of characteristic "Th1" markers by Th17(23) cells underscores the complexity of Th cell lineage specification. Importantly, T-bet^+^Rorγt^+^ Th17 cells are present in lesional tissue in EAE, but also from patients with multiple sclerosis^[@R30]^. Thus, Th17 cells may represent heterogeneous populations comprising the offspring of Th17(β) or Th17(23) cells with distinct trafficking profiles and differing abilities to provoke autoimmune disease. These data are also of interest given the genetic link between *IL23R* polymorphisms and susceptibility to human autoimmune diseases. Future therapies for autoimmune disease should consider the phenotypic characters of pathogenic Th17 cells, generated in the absence of TGF-β, and their signaling pathways as possible targets.

METHODS SUMMARY {#S1}
===============

Mice {#S2}
----

C57BL/6J, B6.Cg-Tg(Cd4-TGFBR2)16Flv/J (CD4dnTGFβRII), C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (TCR(2D2)) and B6.129S6-*Tbx21^tm1Glm^*/J (T-bet^−/−^) mice were purchased from Jackson Laboratory (Bar Harbor, ME), B6.129S6-Rag2*^tm1Fwa^* (Rag2) mice from Taconic (Hudson, NY), *Tgfbr1*^f/f^ mice were bred with CD4-Cre^−^transgenic mice and *Tgfbr1*^f^/^+^CD4-Cre^+^ littermates were used as controls. OT-II CD45.1^+^ mice, BAC-transgenic *Rorc*(γt)-*Gfp*^TG^ mice and *Rorc*(γt)-*Gfp*^TG−^ littermate controls were previously described^[@R6],[@R16]^. All animal studies were performed according to the NIH guidelines for the use and care of live animals and were approved by the Institutional Animal Care and Use Committee of NIAMS or the IACUC of Schering-Plough Biopharma in accordance with guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care.

T cell isolation and differentiation {#S3}
------------------------------------

CD4^+^ T cells from spleens and lymph nodes of 6- to 8-week-old mice were purified by negative selection and magnetic separation (Miltenyi Biotec, Germany) followed by sorting of naive CD4^+^CD62L^+^CD44^−^CD25^−^ population using FACSAria II (BD, NJ). Cells were activated by plate-bound anti-CD3/CD28 (both 10 μg ml^−1^; eBioscience, CA) in serum-free medium for 3--4 days either under neutral conditions or with IL-6 plus IL-1β(each 20 ng ml^−1^) and either human TGF-β1 (0.5 ng ml^−1^; Th17(β)) or IL-23 (50 ng ml^−1^; Th17(23)) (all from R&D Systems, MN). In all cell cultures anti-IFN-γ neutralizing antibodies (10 μg ml^−1^, BD Pharmingen) were added. IL-12 (PeproTech, NJ) was used at 20 ng ml^−1^, huIL-2 at 100 U ml^−1^. Procedures for antagonizing TGF-β-signaling, isolation of lamina propria lymphocytes and CNS-infiltrating lymphocytes are given in Methods.

Flow cytometry, real-time PCR, chromatin immunoprecipitation (ChIP), ChIP-seq, and microarray {#S4}
---------------------------------------------------------------------------------------------

Freshly isolated T cells or naïve T cells activated under the indicated conditions were analyzed. A detailed description of procedures and associated references are given in Methods.

Statistical analysis {#S5}
--------------------

For statistical analysis, all *P* values were calculated with Student's *t*-test and *P*\<0.05 was considered as significant.

**Full Methods** and associated references are available in the online version of the paper.
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![*In vivo* and *in vitro* differentiation of Th17 cells in the absence of TGF-β signaling\
**a,b,** Lamina propria cells were isolated from CD4dnTGFβRII and age-matched wild type (WT) mice (**a**) or T*gfbr1*^f/f^CD4-Cre^+^ and T*gfbr1*^fl+^CD4-Cre^+^ littermate controls (control) (**b**). Cells were stained for T cell markers and intracellular expression of IFN-γ, IL-17A, RORγt and FoxP3. Representative experiments are shown in left panels and pooled data are shown on the right (mean; error bars in **b** denote s.e.m., n=7). No significant differences in absolute numbers and proportions of IL-17A^+^CD4^+^ T cells were noted. \**P*\<0.05. **c--e,** Naïve CD4^+^ T cells were isolated by cell sorting and activated in serum-free media with plate-bound anti-CD3/anti-CD28 for 4 days together with the indicated cytokines. *Il17a* mRNA expression was assessed by quantitative RT-PCR (**c**). IL-17A and IL-2 protein expression were analyzed by intracellular staining. Neutralizing anti-TGF-β antibodies prevented IL-6/IL-1β and TGF-β-dependent differentiation of Th17 cells, but not IL-23 and IL-6/IL-1β induced differentiation. Representative intracellular staining is depicted in panel **d** and pooled data from four individual experiments with mean values are shown in panel **e**. \**P*\<0.05, \*\**P*\<0.01.](nihms231233f1){#F1}

![IL-23 upregulates IL-23R and modifies the *Il17* and *Rorc* loci in the absence of TGF-β\
**a, b,** Naïve CD4^+^ T cells were activated in serum-free media without cytokines, with individual cytokines or cytokine combinations as indicated. *Il23r* expression was analyzed by quantitative RT-PCR (mRNA levels ± s.e.m.) on days 1 to 4 after activation (**a**) or on day 4 only (**b**), \**P*\<0.01, \*\**P*\<0.001. **c,** IL-6 and IL-23 induce Stat3 binding to *Il23r*, histone 3 acetylation (H3Ac) and histone 3 lysine 4 trimethylation (H3K4m3) of the *Il23r* locus as determined by chromatin immunoprecipitation and massive parallel sequencing. **d,** Naïve CD4^+^ cells were activated as in (**a**). Fixed cells were immunoprecipitated with anti-H3K4m3, anti-p300 or anti-H3K9m3 antibodies. Eluted DNA was analyzed by quantitative PCR using primers spanning the promoter regions of *Il17a*, *Il17f* and *Rorc*.](nihms231233f2){#F2}

![IL-23-induced Th17 cells express T-bet but not IL-9 and IL-10\
**a,** Naïve CD4^+^ T cells were polyclonally stimulated in the presence of IL-6, IL-1β and either TGF-β (Th17(β) cells) or IL-23 (Th17(23) cells). Microarray analysis demonstrates the differential expression of genes encoding cytokines and receptors in the two subsets of Th17 cells. Mean values from two independent experiments are shown. **b,** Th17(β) and Th17(23) cells were polarized, expanded in IL-2, restimulated with anti-CD3/anti-CD28 antibodies (1 μg ml^−1^), cytokines, expanded and then analyzed for IL-17, IL-9 or IL-10 expression by intracellular staining. **c,** Transcription factor expression in Th17(β) and Th17(23) cells as assessed by microarray analysis. Mean values of two independent experiments are shown. **d--f,** Th17(23) but not Th17(β) express T-bet. Naïve CD4^+^ T cells were activated by IL-6, IL-1β with either IL-23 or TGF-β. IL-17 expression was not altered in T-bet^−/−^ Th17(β) cells compared to T-bet^+/+^ Th17(β) cells. In contrast, loss of T-bet expression enhanced IL-17 production in Th17(23) cells. A representative experiment is depicted in **d** and pooled data are shown in **e** (n=4) and **f** (n=3, error bars are s.e.m., \**P*\<0.05).](nihms231233f3){#F3}

![RORγt^+^T-bet^+^ Th17 cells arise during CNS inflammation and T-bet-expressing, IL-23-induced Th17 cells are more pathogenic\
a, b, To induce CNS inflammation, we immunized *Rorc*(γt)-*Gfp*^TG^ or *Rorc*(γt)-*Gfp*^TG-^ control mice with MOG35--55 in CFA and CD4^+^ T cells isolated from the draining lymph nodes (dLN) or the CNS were analyzed by flow cytometry for IL-17, T-bet and GFP (RORγt) expression (upper panel). Lower panel shows isotype control staining for T-bet and fluorescence in transgene-negative littermates. A representative staining is depicted in **a** and pooled data of RORγt^+^ T-bet^−^ and RORγt^+^ T-bet^+^ IL-17^+^CD4^+^ T cells are shown in **b** (n=7, \**P*\<0.05). **c,** Naïve CD4^+^Vβ11^+^CD62L^+^CD44^−^ were isolated by cell sorting from TCR(2D2) transgenic mice. The cells were activated with anti-CD3/anti-CD28, IL-6, IL-1β and anti-IFN-γ neutralizing antibodies with either TGF-β1 or IL-23 with anti-TGF-β neutralizing antibodies. The resultant cells were analyzed for IL-17 and IL-10 expression by intracellular staining and flow cytometry. **d,** Polarized cells (1×10^6^) were adoptively transferred into Rag2^−/−^ recipients and followed for signs of neurological disease. Data show mean ± s.e.m. of the EAE clinical score of 20 mice pooled from two independent experiments. **e, f,** CNS-infiltrating mononuclear cells were isolated and the total number of CD4^+^ T cells was determined in both groups (\**P*\<0.01, **e**). The absolute numbers of CNS-infiltrating IL-17^+^ or IFN-γ^+^ CD4^+^ T cells of each group were assessed by intracellular cytokine staining (\**P*\<0.05, \*\**P*\<0.01, **f**).](nihms231233f4){#F4}
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